Company intelligence / Profile preview

Vivasure Medical

Ownership: Private
Development stage: Commercial

Overview

Vivasure’s lead product, PerQseal Elite, received CE Mark approval in Europe. Clinical studies—including the PATCH IDE pivotal study—indicate safety and efficacy for large-hole vascular closure. The system offers a fully absorbable, sutureless solution that simplifies deployment compared to traditional methods. U.S. pivotal data are being presented at major conferences; the product is not yet approved or available for sale in the United States

Therapeutic areas: Cardiovascular
Modalities: DevicePolymer implant
Industry: Implantable Medical Devices

Drug pipeline

3 assets

PerQseal

Commercial

Indications: Large-bore arterial vessel closure

2 more assets in the full pipeline.

Request access →

Partnerships

Haemonetics Corporation – strategic investment with acquisition optionOrchestra BioMed Holdings Inc.

Beyond the preview

Go deeper on Vivasure Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vivasure Medical.

Explore the full profile